Comparison between Goldline Pharmaceutical IPO and Trimoorty Foamtech IPO.
Goldline Pharmaceutical IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Trimoorty Foamtech IPO is a SME Bookbuilding proposed to list at NSE SME.
| Goldline Pharmaceutical IPO | Trimoorty Foamtech IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Cumulative Capital Pvt.Ltd. | Arihant Capital Markets Ltd. |
| Registrar | Bigshare Services Pvt.Ltd. | Purva Sharegistry (India) Pvt.Ltd. |
| Market Maker | Nirman Share Brokers Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | |
| Final Prospectus | Final Prospectus | |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Goldline Pharmaceutical IPO is up to ₹11.02 Cr whereas the issue size of the Trimoorty Foamtech IPO is up to ₹0.00 Cr. The final issue price of Goldline Pharmaceutical IPO is ₹43.00 per share and of Trimoorty Foamtech IPO is .
| Goldline Pharmaceutical IPO | Trimoorty Foamtech IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹41.00 per share | |
| Issue Price (Upper) | ₹43.00 per share | |
| Issue Price (Final) | ₹43.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 3000 shares | |
| Fresh Issue Size | 25,62,000 shares | 28,58,000 shares |
| Fresh Issue Size (Amount) | up to ₹11.02 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 7,14,000 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 25,62,000 shares | 35,72,000 shares |
| Issue Size Total (Amount) | up to ₹11.02 Cr | up to ₹0.00 Cr |
Goldline Pharmaceutical IPO opens on May 12, 2026, while Trimoorty Foamtech IPO opens on . The closing date of Goldline Pharmaceutical IPO and Trimoorty Foamtech IPO is May 14, 2026, and , respectively.
| Goldline Pharmaceutical IPO | Trimoorty Foamtech IPO | |
|---|---|---|
| Anchor Bid Date | May 11, 2026 | |
| Issue Open | May 12, 2026 | |
| Issue Close | May 14, 2026 | |
| Basis Of Allotment (Tentative) | May 15, 2026 | |
| Initiation of Refunds (Tentative) | May 18, 2026 | |
| Credit of Share (Tentative) | May 18, 2026 | |
| Listing date (Tentative) | May 19, 2026 | |
| Anchor Lockin End date 1 | Jun 14, 2026 | |
| Anchor Lockin End date 2 | Aug 13, 2026 |
Goldline Pharmaceutical IPO P/E ratio is 10.47, as compared to Trimoorty Foamtech IPO P/E ratio of .
| Goldline Pharmaceutical IPO | Trimoorty Foamtech IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 79.70 | 99.96 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 57.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 10.47 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹41.28 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 35.83 | 32.58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 38.45 | 23.09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.50 | 0.80 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹4.11 | ₹8.76 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 27.37 | 28.05 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Goldline Pharmaceutical IPO Retail Individual Investors (RII) are offered 9,00,000 shares while in Trimoorty Foamtech IPO retail investors are offered 9,00,000 shares. Qualified Institutional Buyers (QIB) are offered 5,40,000 shares in Goldline Pharmaceutical IPO and 0 shares in Trimoorty Foamtech IPO.
| Goldline Pharmaceutical IPO | Trimoorty Foamtech IPO | |
|---|---|---|
| Anchor Investor Reservation | 7,32,000 shares | 0 shares |
| Market Maker Reservation | 1,38,000 shares | 0 shares |
| QIB | 5,40,000 shares | 0 shares |
| NII | 3,90,000 shares | 0 shares |
| RII | 9,00,000 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 25,62,000 shares | 0 shares |
Goldline Pharmaceutical IPO subscribed 600.53x in total, whereas Trimoorty Foamtech IPO subscribed .
| Goldline Pharmaceutical IPO | Trimoorty Foamtech IPO | |
|---|---|---|
| QIB (times) | 180.22x | |
| NII (times) | 1,662.04x | |
| Big NII (times) | 2,010.60x | |
| Small NII (times) | 980.75x | |
| RII (times) | 881.15x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 600.53x |
